poisar

Stock

aTyr Pharma, Inc. ATYR

$0.56+1.08%

Overview

ATYR market data

Price History

ATYR price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.80
Diluted earnings per share over the trailing twelve months.
Beta
0.90
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-13,549.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.40 – $6.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $56.9M · P/B 1.14 · P/S 299.48.

Company News

10 captured
aTyr Pharma Announces Workforce Reduction Of About 60% To Focus On Efzofitimod Program; Expects $13M Reduction In Annualized Operating Expenses Beginning Q4 2026Benzinga · Aug 7, 2026, 8:10 PM
aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1Benzinga · Aug 7, 2026, 8:06 PM
aTyr Pharma CFO Jill Broadfoot To Step Down Sept. 30, 2026Benzinga · Aug 7, 2026, 8:05 PM
aTyr Pharma Reduces Workforce By ~60%Benzinga · Aug 7, 2026, 8:04 PM
8-K filing — aTYR PHARMA INC (ATYR)SEC EDGAR · Aug 7, 2026, 8:04 PM
aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) EstimateBenzinga · Aug 7, 2026, 8:02 PM
aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To EfzofitimodBenzinga · Jul 31, 2026, 8:50 PM
aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In JuneBenzinga · Jul 15, 2026, 12:07 PM
aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) EstimateBenzinga · May 15, 2026, 12:25 PM
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate UpdateGlobenewswire Inc · May 15, 2026, 12:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock